Lineage Cell Therapeutics, Inc.

LCTX

US53566P1093

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.14 ^USD	+2.70%		-0.87%	+4.59%

Mar. 11	Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting	CI
Mar. 07	Transcript : Lineage Cell Therapeutics, Inc., Q4 2023 Earnings Call, Mar 07, 2024

Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell Small Cap Completeness Index

June 23, 2023 at 12:00 am EDT

Latest news about Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting	Mar. 11	CI
Transcript : Lineage Cell Therapeutics, Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q4 Revenue $8.9M, vs. Street Est of $2.8M	Mar. 07	MT
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Lineage Announces FDA Clearance of IND Amendment for Opc1 Cell Transplant for the Treatment of Spinal Cord Injury	Feb. 13	CI
Lineage Cell Therapeutics Launches $14 Million Registered Direct Offering	Feb. 06	MT
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury	Dec. 18	CI
Transcript : Lineage Cell Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Posts Q3 Revenue $1.2M, vs. Street Est of $2.6M	Nov. 09	MT
Lineage Cell Therapeutics, Inc. Announces to Present Rg6501 Phase 1/2A Results to Be Featured At Eyecelerator At 2023 American Academy of Ophthalmology	23-10-24	CI
Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration	23-10-15	CI
Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients Enrolled in A Phase 1/2A Clinical Study of RG6501	23-10-05	CI
EARNINGS: R&Q Insurance loss swells, Jade Road still selling assets	23-09-29	AN
Lineage Cell Therapeutics, Inc. Announces the Results of Imaging Analyses Demonstrating Evidence of Rapid Improvement in Outside Retinal Structure from A Phase 1/2A Clinical Study of Rg6501	23-09-13	CI
Transcript : Lineage Cell Therapeutics, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q2 Revenue $3.2M, vs. Street Est of $2.2M	23-08-10	MT
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Lineage Cell Therapeutics, Cancer Research UK Report 'Encouraging' Results in Lung Cancer Trial	23-07-24	MT
Lineage Cell Therapeutics and Cancer Research UK Reports Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer	23-07-24	CI
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell 2500 Index	23-06-23	CI
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell Small Cap Completeness Index	23-06-23	CI
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell 3000E Index	23-06-23	CI
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell 3000 Index	23-06-23	CI
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell 3000E Growth Index	23-06-23	CI

Chart Lineage Cell Therapeutics, Inc.

Duration

Period

More charts

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Companyâs programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Retinal Cell & Gene Therapy Innovation Summit

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Lineage Cell Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.14 USD

Average target price

5.2 USD

Spread / Average Target

+356.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LINEAGE CELL THERAPEUTICS, INC.	+4.59%	215M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research